ALX Oncology grants option to director Goodman

ALX Oncology Holdings Inc. reported an insider equity award to director and 10% owner Corey S. Goodman.

Accepted by SEC EDGAR 01/21/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. reported an insider equity award to director and 10% owner Corey S. Goodman. On January 20, 2026, Goodman received a stock option covering 40,400 shares of common stock with an exercise price of $1.32 per share, expiring on January 19, 2036.

The option vests in 12 equal monthly installments beginning on February 20, 2026, meaning the award becomes fully vested over one year. Following this transaction, Goodman beneficially owned 40,400 derivative securities directly in the form of this stock option.

Insider Trade Summary

Grant/Award: 40,400 shares

Grant/Award 1 txn

Insider GOODMAN COREY S

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,400	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,400 contracts (Direct)

Footnotes (1)

1. F1. Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider involved in this ALXO Form 4 filing?

The insider is Corey S. Goodman, who is reported as both a director and a 10% owner of ALX Oncology Holdings Inc.

What type of security did Corey S. Goodman receive from ALX Oncology (ALXO)?

Corey S. Goodman received a stock option (right to buy) derivative security linked to ALX Oncology Holdings Inc. common stock.

How many ALX Oncology (ALXO) shares are covered by the new stock option?

The stock option covers 40,400 shares of ALX Oncology Holdings Inc. common stock.

What is the exercise price and expiration date of the ALXO stock option granted to Corey S. Goodman?

The option has an exercise price of $1.32 per share and an expiration date of January 19, 2036.

When does the ALX Oncology stock option granted to Corey S. Goodman vest?

The shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

How many derivative securities does Corey S. Goodman own after this ALXO transaction?

After this transaction, Corey S. Goodman beneficially owned 40,400 derivative securities, all directly held as this stock option.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOODMAN COREY S

(Last) (First) (Middle)

C/O VENBIO PARTNERS, LLC

1700 OWENS STREET, SUITE 595

(Street)

SAN FRANCISCO CA 94010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.32	01/20/2026		A		40,400		(1)	01/19/2036	Common Stock	40,400	$0	40,400	D

Explanation of Responses:

1. Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

	/s/ Shelly Pinto, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.